The advent of GLP-1 weight-loss medications such as Wegovy and Zepbound has spurred debate as to whether the drugs’ cost should be covered by Medicare,…
Read on
Hospitals across America are shuttering their obstetric units, and the issue is most acute for women served by rural hospitals, a new study finds. By…
Read on
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. “Given…
Read on
Take the stairs. Tote heavy shopping bags. Walk up that hill. Play tag with a kid or a pet. Weaving these tiny bursts of vigorous…
Read on
So-called crisis pregnancy centers, often created with an anti-abortion agenda, are providing pregnant women some questionable medical advice alongside potentially helpful services, a new study…
Read on
The collected evidence is in, and drinking about eight cups of water per day is, in fact, good for you. So says a University of…
Read on
Premature babies not only face serious and immediate health consequences: New research shows they are also more likely to die early, a risk that persists…
Read on
Certain hormone replacement therapy pills appear to increase the risk of heart disease and serious blood clots in women going through menopause, a new study…
Read on
The rate and number of abortions among U.S. women took a slight dip in 2022 compared to 2021, according to the latest data from the…
Read on
The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has found. Zepbound reduced the risk of…
Read on
The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid. However,…
Read on
It’s common to find a pitcher soaking their elbow in an ice bucket following a baseball game, in an effort to save their arm for…
Read on
